Funding for this research was provided by:
Norges Forskningsråd (grant no. 193203)
Article History
Received: 13 September 2018
Accepted: 11 December 2018
First Online: 21 January 2019
Ethics approval
: This study was conducted in accordance with Shanghai Medicilon Inc. standard operating procedures (SOPs). This study would not be considered within the scope of the Good Laboratory Practice Regulations.
: Not applicable.
: EA Dennis is scientific board member of Avexxin AS, B Johansen is CSO of Avexxin AS, and AJ Feuerherm is partly employed by Avexxin AS.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.